Integra LifeSciences (NASDAQ:IART) received a $58.00 target price from Oppenheimer in a research report issued on Tuesday. The firm presently has a “buy” rating on the life sciences company’s stock. Oppenheimer’s target price would suggest a potential upside of 18.78% from the company’s previous close.
A number of other analysts have also recently weighed in on the company. Zacks Investment Research cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 25th. Royal Bank of Canada reiterated a “sector perform” rating and set a $50.00 price target (up from $48.00) on shares of Integra LifeSciences in a research report on Thursday, November 9th. Barclays reiterated an “equal weight” rating and set a $53.00 price target (up from $47.00) on shares of Integra LifeSciences in a research report on Tuesday, September 12th. Wells Fargo & Company cut Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research report on Sunday, October 29th. Finally, J P Morgan Chase & Co cut Integra LifeSciences from an “overweight” rating to a “neutral” rating and set a $44.00 target price on the stock. in a research report on Friday, October 27th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Integra LifeSciences currently has an average rating of “Buy” and an average target price of $53.64.
Shares of Integra LifeSciences (IART) opened at $48.83 on Tuesday. The company has a current ratio of 4.49, a quick ratio of 3.39 and a debt-to-equity ratio of 1.26. The firm has a market capitalization of $3,839.12, a P/E ratio of 27.03, a PEG ratio of 2.15 and a beta of 0.65. Integra LifeSciences has a 1 year low of $39.65 and a 1 year high of $56.42.
In other news, Director Barbara B. Hill purchased 10,768 shares of the firm’s stock in a transaction on Tuesday, October 31st. The stock was purchased at an average cost of $46.66 per share, with a total value of $502,434.88. Following the purchase, the director now owns 55,540 shares in the company, valued at approximately $2,591,496.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Richard D. Gorelick sold 1,500 shares of the stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total value of $70,785.00. Following the transaction, the vice president now directly owns 21,665 shares of the company’s stock, valued at $1,022,371.35. The disclosure for this sale can be found here. 21.50% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of IART. Acrospire Investment Management LLC boosted its stake in Integra LifeSciences by 280.0% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after purchasing an additional 1,400 shares in the last quarter. Riverhead Capital Management LLC boosted its stake in Integra LifeSciences by 49.9% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock valued at $131,000 after purchasing an additional 799 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Integra LifeSciences by 8.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock valued at $150,000 after purchasing an additional 218 shares in the last quarter. Whittier Trust Co. bought a new position in Integra LifeSciences during the 3rd quarter valued at $169,000. Finally, San Francisco Sentry Investment Group CA bought a new position in Integra LifeSciences during the 2nd quarter valued at $174,000. 87.62% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Integra LifeSciences (IART) Given a $58.00 Price Target by Oppenheimer Analysts” was posted by Week Herald and is the property of of Week Herald. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://weekherald.com/2017/12/12/integra-lifesciences-iart-given-a-58-00-price-target-by-oppenheimer-analysts.html.
Integra LifeSciences Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.